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In contrast to conventional chemotherapy, carboplatin is still dosed per unit of body surface area (BSA) in high-dose chemotherapy
protocols in clinical practice. To individualise dosing, a population pharmacokinetic model for poor-risk germ cell tumour patients
receiving 1500mgm
 2 carboplatin was developed. The typical central volume of distribution (19.9l) and typical clearance
(110mlmin
 1) corresponded approximately to the extracellular fluid space or glomerular filtration rate, respectively. The covariate
analysis identified several patient-specific factors. Carboplatin clearance was significantly related to creatinine clearance and body
height, explaining 73% of the interindividual variability. Thus, an equation to predict individual clearance prior to treatment was
developed (CL¼0.41 creatinine clearanceþ1.05 body height 124.4). The relative frequency of developing toxicity increased
significantly with higher AUC values for different types of toxicity. In addition, overall nonhaematological toxicity correlated
significantly with exposure of carboplatin, leading to the assessment of a target AUC. Based on the prediction of individual clearance
and the definition of a target AUC associated with moderate toxicity, an individualised dosing equation is proposed. Retrospectively,
the individualised dosing strategy would have led to a higher dose on average and a broader range to be administered, compared to
empirical dosing per unit BSA in the high-dose setting.
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Anticancer agents are usually dosed per unit of body surface area
in clinical practice. Carboplatin, an active component in poten-
tially curative regimens of different solid tumours, is one of the few
examples that in conventional dosing is not dosed according to
body surface area. For conventional-dose carboplatin, Egorin and
Jodrell (1992) demonstrated significant correlations between
platelet nadir (expressed as the relative change from baseline)
and pharmacokinetics (PK), namely the area under the concentra-
tion–time curve, AUC. Based on the correlations found, they
defined a target AUC associated with a platelet nadir that was
considered to be tolerable. Using this target AUC concept, they
suggested two different dosing formulas depending on whether
patients had been pretreated with chemotherapy or not. Calvert
et al (1989) presented a dosing formula to individualise the dose
based on the patient’s renal function, pretreatment with cytotoxic
agents and chemotherapy protocol (monotherapy or combination
therapy). This dosing formula for conventional-dosed carboplatin
has been approved by regulatory agencies, for example, FDA in
1997. In prospective clinical trials, it was demonstrated that
individualisation resulted in a more precise prediction of the effect
of carboplatin in terms of myelosuppression, especially thrombo-
cytopenia–the dose-limiting toxicity (Jodrell et al, 1992; Gore et al,
1998). In high-dose chemotherapy (HDCT) followed by autologous
stem cell rescue (ASCR), however, myelosuppression is no longer
the dose-limiting toxicity. Other types of toxicity will have to be
considered instead (Wright et al, 1995; Huitema et al, 2002; Kloft
et al, 2002), and the therapeutic index for the patients has to be
newly defined. Although the Calvert dosing formula has been
applied to high-dose treatment (Motzer et al, 2000), so far
pharmacokinetic/pharmacodynamic analysis is rare (Huitema et al,
2002). In germ cell cancer patients, high-dose chemotherapy is a
highly valuable option for poor-risk patients (Siegert et al, 1998;
Rodenhuis et al, 1999). We therefore performed a study in this
patient population in order to investigate comprehensively the
population pharmacokinetics and pharmacokinetics-toxicity rela-
tionships of high-dose carboplatin, resulting in an individualised
dosing recommendation. In addition, a comparison with existing
strategies was carried out.
PATIENTS AND METHODS
Patient selection/enrolment
Eligibility for HDCT with ASCR required a histologically or
tumour marker proven germ cell tumour, multiple relapse and/or
refraction to prior chemotherapy, a Karnofsky index X60% and an
age X18 years. Patients were not recruited if one or more organs
were more than slightly impaired (kidney, e.g., 1.3-fold of
reference value or creatinine clearance o70mlmin
 1, liver, lung,
heart and bone marrow), or the bone marrow was infiltrated by the
tumour. Prior to HDCT, all patients had received cisplatin-based
conventional dose chemotherapy. The last cycle consisted of either
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lcisplatin, etoposide and ifosfamide (PEI) or cisplatin, ifosfamide
and paclitaxel (TIP).
Prior to start of the study, the protocol was approved by the
Ethics Committee of the University hospital and all patients gave
written informed consent.
Treatment protocol
The HDCT protocol for the treatment of germ cell tumour patients
consisted of 500mgm
 2day
 1 carboplatin as a 1-h i.v. infusion for
three consecutive days: days  6t o 4 (i.e., in total 1500mgm
 2).
If renal function was mildly impaired prior to HD treatment, that
is, a creatinine clearance of 70–85mlmin
 1, the carboplatin dose
was reduced by 20%. Carboplatin administration was followed by
etoposide (600, or 450mgm
 2day
 1 in renal impairment, as a 1-h
i.v. infusion for 4 days: days  6t o 3) and a third cytotoxic agent
that was either ifosfamide (2500mgm
 2day
 1 as a 22-h i.v.
infusion for 4 days: days  6t o 3, i.e, CEI regimen) or thiotepa
(250 or 150mgm
 2day
 1 as 1h- i.v. infusion for 3 days; days –6
to –4, i.e., CET regimen). At 3 days after the last etoposide
administration on day 0, an ASCR was performed. Stem cells were
either recruited from bone marrow or peripheral blood after
stimulation with G-CSF. In addition, patients received supportive
drug treatment, for example, antiemetic, uroprotective (with
MESNA, only in the CEI regimen), anti-infective and hyperur-
icemia prophylaxis.
A total of 29 patients were treated according to the protocol. The
summary statistics of the patients’ characteristics are listed in
Table 1. Typical of this malignancy, the median age was 33years
(range 20–54 years). In all, 23 patients received the full HDCT
regimen (12 CEI regimen, 11 CET regimen) and six the reduced
regimen due to a mild renal impairment prior to HDCT (all CET
regimen). As ASCR, in 10 patients bone marrow was retrans-
planted while in 19 patients peripheral blood stem cells were
retransfused.
Sample collection and bioanalysis
For the determination of PK parameters, serial blood samples were
drawn from the beginning of the HDCT until the day of the ASCR
at the following time points: prior to and at 0, 7 and 23h after the
end of the first and second carboplatin infusion, as well as 10, 20
and 30min after the start and 0, 1.5, 4, 7, 11, 23, 27, 35 and 96h
after the end of the third infusion (group 1). After the first 10
patients, an optimised schedule was applied, that is, prior to and at
0, 1.5, 2.5, 4, 7, 11, 21h after the end of the first infusion, 0 and 23h
after the end of the second and 0, 1.5, 4, 7, 11, 23, 35, 44, 56, 72 and
96h after the last infusion (group 2). For PK parameter estimation,
the actual time points of sample collection were considered.
Sample pretreatment at the hospital and the bioanalytical
methods for the determination of platinum have been described
in detail previously (Kloft et al, 1999). In short, blood samples were
centrifuged and plasma was further centrifuged either in
Centrisartt (Sartorius, Goettingen, Germany) or in Centrifreet
tubes (Millipore, Eschborn, Germany) to prepare ultrafiltered
plasma aliquots where the platinum species not bound to
macromolecules could be analysed. All aliquots were stored at
 701C until analysis. The validated flameless atomic absorption
spectrometry (FAAS) method for the determination of platinum in
ultrafiltrate only required 40ml sample volume of the patient. The
calibration curve of the assay was linear from 0.021 to 32000mg
Ptml
 1 with coefficients of variation of 1.2–7.3 and 2.9–8.6% for
within-day and between-day precision, respectively, across the
concentration range (Kloft et al, 1999).
Population pharmacokinetic data analysis
For the determination of PK parameters of carboplatin, the
measured platinum concentrations were multiplied by the molar
mass ratio 1.903 (carboplatin:platinum) in order to compare them
with the results of other authors. Pharmacokinetic analysis was
carried out using the software P-Pharmt version 1.4 (SIMED,
Cre ´teil Cedex, France). Ultrafiltrate concentration–time data of all
patients were simultaneously evaluated in order to characterise the
PK profile of the patient population with mean and variability PK
parameters (basic PK model). The variability parameters included
interindividual (between patient) variability, assumed to be
normally distributed (Po0.05, Shapiro–Wilk test for normality)
and modelled as additive error, and residual (within one patient)
variability modelled as proportional heteroscedastic error. In
addition, a covariate analysis was performed. Several patient-
specific factors (covariates) were evaluated for displaying a
significant influence on PK parameters. The aim was to find and
to quantify the relationships between covariates and the individual
predicted PK parameters. The covariates tested included age, body
weight, body height, body surface area (BSA), concomitant
medication of ifosfamide and various measures of kidney function.
A stepwise multiple regression analysis implemented in the
software P-Pharmt was performed according to the following
equation (Draper and Smith, 1966):
Pij ¼ a þ b1z1i þ b2z2i þ   þbnzni ð1Þ
where Pij is the ith individual predicted PK parameter j, a the
intercept, bn the coefficient for the nth covariate found to be
significant and zni the ith individual nth covariate. On each step,
the covariate with the highest partial correlation coefficient was
entered into the regression equation. At every stage of the
procedure the contribution of each covariate, entered at the
current step or previously, was examined. An ANOVA was
performed for statistical significance, retaining or rejecting the
covariates based on their partial F values (Draper and Smith,
1966). The procedure was finished if no covariate could either be
entered or rejected from the regression equation (Draper and
Smith, 1966; Gomeni et al, 1994). Significant covariates identified
were finally included into the PK model (final PK model). Mean PK
parameters and significant covariates were regarded as fixed-
effects parameters and interindividual and residual variability as
random-effects parameters.
For each step the explained percentage of the interindividual
variability of a significant covariate was calculated according to
(Draper and Smith, 1966):
%explainedvariability ¼
Pn
i¼1½Pi;cov   Pcov 
2
Pn
i¼1½Pi   P 
2  100 ð2Þ
where n is the number of patients, Pi is the individual model
predicted PK parameter and P is the mean population PK
parameter, that is, both according to the basic PK model. Pi, cov
is the individual predicted PK parameter according to the covariate
model (eq. 1) and Pcov is the respective mean value.
Table 1 Summary table of patient characteristics
Demographics n x ¯ s RSD (%) x ˜ I80
Age (years) 29 34.0 8.7 25.6 32.9 20.9
Weight (kg) 29 76.7 14.5 18.9 74.0 41.2
Height (cm) 29 178.5 7.1 4.0 178.0 18.4
BSA (m
2) 29 1.9 0.2 9.6 1.9 0.5
Creatinine conc. (mgdl
 1) 29 0.96 0.15 15.6 0.90 0.36
  x x¼arithmetic mean; s¼standard deviation; RSD¼relative standard deviation;
~ x x¼median; I80¼difference between the 9th and 1st decile, that is, the range that
covers 80% of sample distribution.
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Toxicity of various organs (heart, lung, liver, kidney, skin, ear),
central and peripheral nervous system (CNS, PNS), and GI tract
motility was evaluated daily according to modified WHO
classification criteria (categorical scale: 0–4, where grade 0
represents no toxicity and grade 4 life-threatening toxicity
(McGuire, 1979)). Apart from serum creatinine concentration,
renal function was further assessed by creatinine clearance,
estimated for all 29 patients (Cockcroft and Gault, 1976) and
determined by a 24-h urine collection, CLCR24h, n¼26, as well as
by
51Cr-EDTA clearance, n¼25.
In order to examine whether there was a higher probability of a
patient experiencing a certain type of toxicity if exposure of
carboplatin was higher, the occurrence of toxicity was related to
the area under the concentration–time profiles (AUC) of high-
dose carboplatin calculated from individual PK analysis. For this
purpose, groups of patients with different AUC values were
formed, and for each of the groups the relative frequency of
patients developing toxicity was calculated.
Dose individualisation
Development of an individualised dosing strategy was based on the
target AUC concept and individual clearance prediction.
Target AUC
For the patient population investigated, the decision for a target
AUC value was based on the relationships between AUC and
toxicity, that is, the target AUC determined will then result in a
certain extent of toxicity.
Individual CL prediction
For conventional carboplatin, there are various strategies for
predicting individual clearance. The predictive performance of the
two most important strategies, proposed by Calvert et al (1989)
and Chatelut et al (1995), for predicting carboplatin CL of the
HDCT patients studied was evaluated using the mean prediction
error (MPE) as a measure of bias and the root mean squared
prediction error (RMSE) as a measure of precision according to
(Sheiner and Beal, 1981)
MPE ¼
Pn
i¼1½PEi 
n
¼
Pn
i¼1½CLi;pred   CLi;est 
n
ð3Þ
RMSE ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ Pn
i¼1½PEi 
2
n
s
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ Pn
i¼1½CLi;pred   CLi;est 
2
n
s
ð4Þ
where n is the number of patients i and PE is the prediction error
of each pair, that is, the difference between the predicted and the
estimated (individual model predicted found in this study) value,
CLi, pred CLi,e s t .
The Calvert and Chatelut equations for male subjects are as
follows:
CL ¼ GFR þ 25 ð5Þ
where the GFR is the glomerular filtration rate (mlmin
 1) and
CL ¼ 0:134 bodyweight
þ
218 bodyweightð1   0:00457 ageÞ
serumcreatinine
ð6Þ
Here, serum creatinine concentration has to be in mM. Originally,
Calvert et al based the GFR determination on the clearance of
51Cr-
EDTA. As other authors have suggested using creatinine clearance
for GFR instead for practical purposes, creatinine clearance based
on the Cockcroft–Gault equation (CLCRCG) and on the 24-h urine
collection (CLCR24h) were investigated as well.
Statistical methods
If not stated otherwise, all data are presented as mean7s.d. (s).
The data were analysed using the software programs STAT-
GRAPHICS Plust version 1.0 (Manugistics, Rockville, MD, USA),
S-STAT Packaget version 4.0 (SIMED, Cre ´teil Cedex, France) and
SPSSt version 7.5 (SPSS Inc., Chicago, USA). A P-value of p0.05
was considered statistically significant.
RESULTS
All 29 patients entering the study were evaluated and are reported
in the following.
Population PK
In total, 557 ultrafiltrate concentration–time data were available
for the population PK analysis. The number of observations per
patient ranged from 13 to 23. Figure 1 shows the concentration–
time profile of all data sets. An open two-compartment model with
zero-order input and first-order elimination from the central
compartment best described the data. The basic PK parameters of
clearance (CL), central volume of distribution (Vc) and the transfer
rate constants (k12, k21) are listed in Table 2 (left part). The
population PK was characterised by a mean CL of 110mlmin
 1
that corresponded approximately to the glomerular filtration rate
of the kidney. Regarding interindividual variability, the error
variance was lowest for Vc and highest for CL and k12. The residual
variability was 6.8%. Individual Bayesian PK parameters, that is,
individual predicted PK parameters, were generated based on the
population parameters of the model and on the individual
concentration–time data. The covariate analysis investigating the
relationships between the patient-specific factors and individual
predicted PK parameters selected several covariates as influential
on CL, Vc and k12 but not on k21 (Table 3). Creatinine clearance
determined by the 24-h urine collection method (CLCR24h)
explained almost two-thirds of the interindividual variability of
CL. The inclusion of body height, increased explained variability to
73%. If weight was included in the analysis instead of height, only
renal function remained as a significant covariate for CL. Renal
function determined by
51Cr-EDTA clearance was less explanatory
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Figure 1 Time course of all measured concentrations in ultrafiltered
plasma after the three carboplatin infusions (n¼557).
Individualised dosing for high-dose carboplatin
C Kloft et al
789
British Journal of Cancer (2003) 89(5), 787–794 & 2003 Cancer Research UK
C
l
i
n
i
c
a
l(only 29%) than CLCR24h, which was closely monitored in clinical
routine in the HDCT patients. The covariates selected were then
included in the PK model in order to establish the final
relationships between the covariates and the PK parameters. The
final mean and variability PK parameters are summarised in
Table 2 (right part). The unexplained interindividual variability
was most reduced for CL, that is, more than 40%. In Figure 2, the
population predicted concentrations, based on the final model, are
plotted against the measured concentrations. The values below
24mgml
 1 were relatively symmetrically distributed around the
line of identity, indicating that the PK model adequately described
the PK profile of HD carboplatin. Although in the high
concentration range an underprediction can be observed suggest-
ing, for example a three-compartment model, a two-compartment
model resulted in a better fit to the data. Closer examination of
these values, obtained from a few individuals directly at the end of
the infusions, in an individual PK analysis revealed, for some
patients, that a three-compartment model gave better results with
an additional extremely short ‘distribution’ phase just after the end
of the infusions.
Correlation of PK and toxicity
All patients experienced various types of toxicity of WHO grades
X1. If patients already showed a grade X1 toxicity prior to
therapy, only the difference was considered. All patients developed
grade 4 haematotoxicity, but haematological recovery was
successful in all. Other types of toxicity did not occur in all
patients.
As explorative examination of a relation of AUC values, ranging
considerably from 16.4 to 42.0mgminml
 1 with approximately
75% of the values between 21.7 and 29.2mgminml
 1, and the
occurrence of toxicity, the relative frequency of five groups of
patients with different AUC values (three groups within the range
covering the 75% sample distribution as well as one group with
lower and one with higher values) is illustrated in Figure 3. For
PNS toxicity, the analysis was performed with grades 4 1 since
almost all patients developed at least grade 1 PNS toxicity. For
nephrotoxicity, ototoxicity and PNS toxicity, the relative frequency
of developing toxicity was increased with higher exposure, most
pronounced for renal toxicity. No patient in the lower three AUC
groups experienced renal toxicity, whereas 25% of the patients
with AUC values between 26.7  29.2mgminml
 1 and 75% with
AUC values above 29.2mgminml
 1 developed renal toxicity. Due
to the small number of patients and the explorative nature of the
examination, no further statistical analysis was performed.
In addition, the maximum therapy-associated toxicity
grades were evaluated in relation to exposure. As a measure of
the extent of overall nonhaematological toxicity for each patient,
all individual toxicity scores were added. This individual sum
of the overall nonhaematological toxicity was related to the
Table 2 Population pharmacokinetic parameters of the basic PK (without covariates) and final PK model
(with covariates)
Basic model Final model (according to Eq. 1)
Parameter Mean Variance Mean Variance Intercept Coefficient(s)
CL 110.0 493 110.5
a 171  124.4 CLCR24h: 0.408
(mlmin
 1)
Height: 1.05
Vc 19.8 3.6 19.9
a 2.5 12.9 Weight: 0.091
(l)
k12 0.042 1.3 10
 4 0.042
a 6.6 10
 5  2.6 10
 2 Weight:  4.7 10
 4
(h
 1) Height: 7.5 10
 4
Age:  6.4 10
 4
CLCR24h:  8.1 10
 5
k21 0.024 2.1 10
 5 0.023 2.1 10
 5 ——
(h
 1)
aFor a patient with average values of the covariates.
Table 3 Selected covariates with influence on the pharmacokinetic
parameters
Parameter Covariate Explained interindividual
variability (%)
CL CLCR24h 63
CLCR24h and body height 73
Vc Body weight 63
k12 Body weight 23
Body weight and body height 47
Body weight, body height and age 63
Body weight, body height,
age and CLCR24 h
68
k21 None 0
CLCR24h¼creatinine clearance determined by the 24-h urine collection method.
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Figure 2 Correlation between measured and model-predicted concen-
trations in ultrafiltered plasma (n¼557).
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lAUC of carboplatin. As illustrated in Figure 4, the Pearson
correlation coefficient between exposure and overall nonhaema-
tological toxicity was statistically significantly different from zero
(Po0.01).
Dose individualisation
Target AUC The patient population displayed a large difference
(2.6-fold) in AUC values. If almost no toxicity is to be accepted, a
low(er) target AUC of approximately 24mgminml
 1 might be
considered. Based on the significant correlation between AUC and
the overall nonhaematological toxicity, we suggest a target AUC in
the order of 26–27mgminml
 1. This target AUC, that is exposure
of carboplatin, is associated with moderate occurrence of toxic
effects. A higher AUC would be associated with a higher risk of
(unacceptable) toxicity. The patient with the highest AUC value of
42.0mgminml
 1 suffered from multiple grade 3–4 toxicities,
which further strengthens the demands of a tailored dose
according to a target AUC.
Individual CL prediction The results of predictive performance of
the four established strategies for conventional carboplatin are
presented in Table 4. All methods for predicting the CL of the
patients in this study exhibited relatively poor precision (RMSE at
least 30mlmin
 1). Methods 1, 2 and 4 resulted in pronounced
biased predictions, that is, the CL values were largely over-
estimated. The ‘original’ Calvert equation (method 3) yielded
unbiased predictions on average, that is there was no systematic
error, but the individual predictions deviated from the respective
individual estimates between  49 and 101mlmin
 1. The Chatelut
equation showed the highest deviations regarding accuracy and
precision.
Since all methods for conventional carboplatin dosing did not
predict CL in high-dose treatment satisfactorily, a new prediction
method for individual CL is proposed. The equation is based on
the results of the covariate relationships of the final PK model:
CL ¼ 0:41 CLCR24h þ 1:05 bodyheight   124:4 ð7Þ
CLCR24h (inmlmin
 1) and body height (in centimeter) were the
only patient-specific factors influencing individual clearance
(mlmin
 1) resulting in a good predictive performance (MPE
 4.1mlmin
 1; RMSE 16mlmin
 1). One has to keep in mind that
these values are based on the developed equation.
Individual dosing calculation
Based on the relationship between the PK parameters CL and AUC,
and dose as D¼CL AUC, an individualised carboplatin dosing
equation was derived from the equation of the individual predicted
clearance (eq. 7) and a target AUC associated with a moderate
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Figure 3 Relative frequency of five groups with patients of certain
carboplatin AUC values to develop nephrotoxicity, ototoxicity and PNS
toxicity (n¼5,6,7,8,3, respectively, starting with the group of lowest AUC
values).
12 16 20 24 28 32 36 40 44
0
8
16
24
O
v
e
r
a
l
l
 
n
o
n
h
a
e
m
a
t
o
l
o
g
i
c
a
l
 
t
o
x
i
c
i
t
y
r = 0.77
Carboplatin AUC (mg min ml−1)
Figure 4 Overall nonhaematological toxicity in relation to AUC of
carboplatin (n¼29).
Individualised dosing for high-dose carboplatin
C Kloft et al
791
British Journal of Cancer (2003) 89(5), 787–794 & 2003 Cancer Research UK
C
l
i
n
i
c
a
ltoxicity of 26.6mgminml
 1, as an example for clinical practice:
Dind ¼ 11 CLCR24h þ 28 bodyheight   3309 ð8Þ
where Dind is the individual carboplatin dose in milligram. Since it
was our aim to propose a simple dosing guideline calculation for
clinical practice, in the final individual dosing equation figures
have been rounded off. Evaluation of the rounding effect showed
only marginal differences. If one is determining patient’s height,
creatinine clearance (24-h collection urine) and a target AUC (here
26.6mgminml
 1), the individualised carboplatin dose can be
calculated prior to high-dose treatment. The equation developed is
only applicable for patients with normal or slightly impaired renal
function, that is, for patients usually receiving carboplatin.
Retrospectively, the proposed equation was applied to the HDCT
patient population investigated and compared to the empirical
BSA-based carboplatin doses administered in the study. The
empirical dosing, multiplying the protocol dose of 1500mgm
 2
with the BSA of the patient, resulted in an average absolute
carboplatin dose of 2757mg (range 1950–3300mg, Table 5). The
corresponding individualised carboplatin dose taking the indivi-
dual creatinine clearance and height into consideration was
approximately 100mg higher. Thus, on average, a higher dose
could have been administered. The minimum and maximum
individualised doses were lower or higher than the empirical ones,
respectively. Comparing the empirical and individualised dosing
for each patient separately, in two-thirds of the patients the doses
differed by more than 5% up to 35%.
DISCUSSION
Dosing in cancer chemotherapy is traditionally based on BSA and,
even nowadays, most new drugs are approved in doses per unit
BSA. In 1990, Grochow et al (1990) have highly questioned the
rationale of this dosing strategy and thereby stimulated research in
this field. A prerequisite for improved dosing is the study of the PK
and their relationships to the effects. For conventional carboplatin
dosing, many authors have thoroughly investigated the PK in
different patient populations (adults and paediatrics; Shea et al,
1989; Newell et al, 1993) and also a population PK analysis was
performed (Chatelut et al, 1995). For individualising carboplatin in
HDCT, we have developed a population PK model to characterise
the population and the variability. Analogous to individual data
analysis (Shea et al, 1989; Kloft et al, 2002; Newell et al, 1987; van
Warmerdam et al, 1996b), the population PK model did not
include any nonlinear process for high-dose carboplatin. Compar-
able to conventional dosing, the central volume of distribution
appeared to correlate approximately with the extracellular fluid
space, and CL corresponded approximately to the GFR of kidneys
(Chatelut et al, 1995). Regarding interindividual variability, we also
found it highest for CL, that is, AUC, and k12 (Chatelut et al, 1995).
To reduce interindividual variability, we performed an analysis to
identify significant covariates and assess their magnitude of
influence on interindividual variability. CLCR24h was the best
predictor for carboplatin CL. Others have proposed
51Cr-EDTA or
serum creatinine concentration as a marker instead (Chatelut et al,
1995; van Warmerdam et al, 1996a; Wright et al, 2001). If we
excluded CLCR24h we also found these covariates to be significant;
both markers were however less predictive. Although collection of
24-h urine is generally considered to be imprecise (van
Warmerdam et al, 1996a), we feel that for HDCT or other patient
populations where an accurate determination of fluid balance is
daily routine, the urine collection method should be preferred.
Interestingly, BSA was not identified as significantly influencing
CL of the population investigated. The formula to determine BSA
and the derived nomogram most commonly used in clinical
practice were developed at the beginning of the last century
including only nine nonobese adults (DuBois and DuBois, 1916).
Later examinations have shown either an over- or underprediction
of the actual determined BSA (Gehan and George, 1970; Mitchell
et al, 1971). Moreover, the appropriateness using BSA in dose
calculations has been questioned for many anticancer agents
(Reilly and Workman, 1994; Baker et al, 1995; Ratain, 1998).
Except for docetaxel, where BSA has been found to be a main
predictor for clearance (Bruno et al, 1996), recent investigations on
various drugs demonstrated that BSA is poorly correlated with
pharmacokinetic parameters (de Jongh et al, 2001; Loos et al, 2000;
Mathijssen et al, 2002). Although in our study height, also a
measure of body size, was identified as the second significant
covariate of clearance, it accounted for only approximately 10% of
the variability between patients, while weight was not selected at
all. For volume of central compartment only weight, but neither
height nor BSA, was a significant covariate. Thus, our data clearly
suggest that BSA is not a rational factor to base high-dose
carboplatin dosing upon.
In terms of PK-effect relations, we focused on exposure–toxicity
relationships. Generally, carboplatin is considered to be less toxic
than cisplatin concerning the effects on kidney, ear and the
nervous system (Go and Adjei, 1999). In high-dose carboplatin,
however, nephrotoxicity, ototoxicity and neurotoxicity also
become significant as reported by others, too (Wright et al,
1995). Nephrotoxicity is considered to be the most frequent and
dose-limiting toxicity while being reversible in the majority of
patients. In our study, we found an increased probability of a
patient developing nephrotoxicity, ototoxicity or PNS toxicity with
increased AUC values, which was most pronounced for nephro-
toxicity. Huitema et al (2002) also demonstrated a significant
relationship between carboplatin AUC and ototoxicity. In another
study with high-dose carboplatin as continuous infusion, higher
steady-state concentrations were associated with a more frequent
occurrence of renal impairment (Wright et al, 1995).
In addition to the relations of individual types of toxicity, we
found a statistically significant correlation between AUC and
overall nonhaematological toxicity associated with the high-dose
treatment. Thus, a patient with higher carboplatin exposure is
more likely to experience ‘more’ toxicity in terms of more severe
Table 4 Predictive performance of different methods to predict
individual clearance of patients treated with high-dose carboplatin
Method Description
Precision
(RMSE in
mlmin
 1)
Bias
(MPE in
mlmin
 1)
1 Calvert (eq. 5): GFR as CLCRCG 38 +32
2 Calvert (eq. 5): GFR as CLCR24h 37 +27
3 Calvert (eq. 5): GFR as CL51Cr-EDTA 30 +1.3
4 Chatelut (eq. 6) 72 +67
(Eq. 7) Based on CLCR24h and body height 16  4.1
CLCRCG¼creatinine clearance based on the Cockcroft–Gault equation;
CLCR24h¼creatinine clearance determined by the 24-h urine collection method
CL51Cr-EDTA¼
51Cr-EDTA clearance; RSME¼root mean squared predic-
tion error; MPE¼mean prediction error.
Table 5 Comparison of different dosing strategies for the patient
population investigated: empirical vs individualised dosing
Empirical dosing:
Dosing based on
1500mgm
 2 (BSA)
Individualised dosing:
Dosing based on the
proposed equation (eq. 8)
  x x 2757mg 2859mg
Minimal dose 1950mg 1899mg
Maximum dose 3300mg 4069mg
Individualised dosing for high-dose carboplatin
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land/or more different types of toxicity. Although it is not common
to add toxicity grades, we think that this method is of great
interest, and can be justified since the WHO classification system
provides a 5-grade scale for all types of toxicity from none to life-
threatening toxicity. Based on our results, a target AUC associated
with acceptable toxicity (low to moderate) in the range of 24–
27mgminml
 1 is proposed, approximately 4–5-fold higher
compared to the target values proposed for conventional-dose
carboplatin (Calvert et al, 1989). Several groups have applied the
Calvert formula to calculate carboplatin doses for patients
undergoing ASCR using empirically elevated target AUC values
ranging from 12–32mgminml
 1 (Rodenhuis et al, 1999; Chatelut
et al, 2000; Motzer et al, 2000). While Rodenhuis et al used a fixed
target AUC of 20mgminml
 1 leading to manageable toxicity,
Motzer et al performed a target AUC escalation cohort study with a
desired target AUC of 12–32mgminml
 1 using
99MTc-DTPA CL.
The group reported moderate toxicity and that the measured AUC
values did not reach the desired target AUC. In fact, instead of the
target 32mgminml
 1, the actual measured AUC values in this
cohort were only 13, 22 and 23mgminml
 1. Our proposed target
AUC range based on PK data analysis corresponds very well to
these results, and the exemplary target AUC value of
26.6mgminml
 1 represents a moderate dosing strategy with
regard to toxicity and thus might avoid underdosing. The two
patients with the lowest carboplatin AUC in our study unfortu-
nately experienced progressive disease directly after HDCT. If a
more aggressive strategy is to be applied, the target AUC must be
selected below 42mgminml
 1 as toxicity associated with this AUC
was too severe, leading to multiorgan dysfunction in one patient.
The second PK parameter to be controlled for dose individua-
lisation is CL. As has been reported by others, neither the Calvert
nor the Chatelut formula predicted clearance of high-dose
carboplatin without bias and/or imprecision (van Warmerdam
et al, 1996a; Motzer et al, 2000). Interestingly, Chatelut et al, 2000
has recently published an investigation where an empirical target
AUC of 20mgminml
 1 and individual clearance based on the
formerly developed equation was used. Unlike in our study, the
Chatelut formula adequately estimated carboplatin clearance.
Chatelut et al (2000) also proposed a very versatile limited
sampling strategy of two samples only, which represents an
attractive approach in future studies.
Dose individualisation based on target AUC and individual CL is
often associated with lowering the dose. In contrast, this strategy
aims to adjust the dose to achieve a target AUC based on patient-
specific factors. Compared to empirical dosing based on BSA, the
proposed tailored dose represented an increase in more than 40%
and a decrease in only 24% of the patients. Individualised dosing
taking renal function, body height and an acceptable toxicity into
account therefore results in a wider dose range than the empirical
dosing. A priori adaptive dosage determination based on the
relative contribution of identifiable patient-specific characteristics
and a reasonable target AUC might therefore result in a more
favourable outcome. A dosage formula based on the retrospective
analysis of the PK of carboplatin in 29 patients has been developed,
which should be further evaluated in patients with different types
of tumour and chemotherapy regimens and finally in prospective
randomised trials.
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